Intra-Cellular Therapies (NASDAQ:ITCI) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Intra-Cellular Therapies (ITCI) operate in?

Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.

Open	$82.64
Close	$83.35
Volume / Avg.	703.93K / 552.90K
Day Range	$81.90 - $83.49
52 Wk Range	54.17 - 93.45
Market Cap	$8.84B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	51
Short Interest	2.55%
Days to Cover	3.56

Recent News

Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile.

Vandana Singh

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Avi Kapoor

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug

Sep

Oct

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$82.64
Close	$83.35
Volume / Avg.	703.93K / 552.90K
Day Range	$81.90 - $83.49
52 Wk Range	54.17 - 93.45
Market Cap	$8.84B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	51
Short Interest	2.55%
Days to Cover	3.56

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Intra-Cellular Therapies (ITCI) stock?

You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.

View our list of the best stock brokerages

Who are Intra-Cellular Therapies (ITCI) competitors?

Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Merck & Co (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).

What is the forecast, or price target, for Intra-Cellular Therapies (ITCI) stock?

Intra-Cellular Therapies has a consensus price target of $94.40.

What is the current price for Intra-Cellular Therapies (ITCI)?

The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $83.35 last updated November 19, 2024 at 4:00 PM EST.

Does Intra-Cellular Therapies (ITCI) pay a dividend?

There are no upcoming dividends for Intra-Cellular Therapies.

When is Intra-Cellular Therapies (NASDAQ:ITCI) reporting earnings?

Intra-Cellular Therapies’s Q4 earnings are confirmed for Thursday, February 20, 2025.

Is Intra-Cellular Therapies (ITCI) going to split?

There is no upcoming split for Intra-Cellular Therapies.

What sector and industry does Intra-Cellular Therapies (ITCI) operate in?

Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Intra-Cellular Therapies

Intra-Cellular Therapies (ITCI) Forecast